EuroSIDA Cabotegravir+Rilpivirine Utilization Study
Research type
Research Study
Full title
Drug Utilization, Adherence, Effectiveness and Resistance: A Retrospective/Prospective Observational Cohort Study in People Living with HIV (PLWH) Initiating ARV Regimen CAB+RPV LA in Collaboration with EuroSIDA
IRAS ID
357581
Contact name
Marta Boffito
Contact email
Sponsor organisation
Centre of Excellence for Health, Immunity and Infections (CHIP)
Duration of Study in the UK
5 years, 7 months, 31 days
Research summary
This observational cohort study will collect prospective and retrospective injection data from HIV patients who have started cabotegravir + rilpivirine long-acting (CAB+RPV LA) treatment after 2020. Prospective collection of follow up data will continue until at least the end of 2025 and until 2030 depending on the available funding.
The study includes patients from a real-world clinical setting, will aim to understand better the individual population receiving CAB+RPV LA containing regimens in routine clinical practice, usage patterns, adherence, durability, post-marketing clinical effectiveness of these regimens and monitor for resistance among virologic failures for whom data on resistance testing are available.REC name
London - Fulham Research Ethics Committee
REC reference
25/LO/0691
Date of REC Opinion
12 Nov 2025
REC opinion
Further Information Favourable Opinion